THE THERAPEUTIC CHALLENGE IN SYSTEMIC TREATMENT OF ADVANCED AND RECCURENT ENDOMETRIAL CANCER
More than 300 000 new cases of endometrial cancer (EC) are registered annually in the world. The prognosis for EC is determined by the stage of the disease. In Russia, stage III–IV EC is diagnosed in 16 % of patients, with the mortality rate in the first year of follow-up of 9.2 %. The management of...
Main Authors: | I. Y. Bazaeva, S. V. Khokhlova, A. A. Fedenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2018-03-01
|
Series: | Сибирский онкологический журнал |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/672 |
Similar Items
-
Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01) -
Results of surgical treatment of atypical endometrial hyperplasia
by: O. A. Gornykh, et al.
Published: (2014-07-01) -
Expanding therapeutic opportunities for progressive uterine cancer: clinical experience
by: A. G. Kedrova, et al.
Published: (2022-05-01) -
COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01) -
Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review)
by: D. N. Kravchenko, et al.
Published: (2018-10-01)